Vitiligo-like depigmentation following neoadjuvant chemotherapy combined with pembrolizumab in early triple-negative breast cancer: a case report - Top-Institutions - MDSpire

Depigmentation resembling vitiligo after neoadjuvant chemotherapy and pembrolizumab in early-stage triple-negative breast cancer: a case study

  • By

  • Yinglei Deng

  • Dahua Mao

  • Shaogang Zhang

  • Jing Wang

  • July 20, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    our institution
    our institution

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #2

    outside institution
    outside institution

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #3

    Barts Cancer Institute, Queen Mary University of London
    Barts Cancer Institute, Queen Mary University of London

    London, England

    Key Differentiators

    • Oncology

  • #4

    University of Milan
    University of Milan

    Milan, Italy

    Key Differentiators

    • Oncology

  • #5

    European Institute of Oncology
    European Institute of Oncology

    Milan, Italy

    Key Differentiators

    • Oncology

Original Source(s)

Vitiligo-like depigmentation following neoadjuvant chemotherapy combined with pembrolizumab in early triple-negative breast cancer: a case report

  • by Yinglei Deng, Dahua Mao, Shaogang Zhang, Jing Wang

  • July 20, 2026

Related Content

ORC6 marks a replication-active malignant epithelial state and is associated with immune-low features in oral squamous cell carcinoma

Retraction Note: Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway

Case Report: Diagnosis and treatment report and literature review of 2 cases of VHL-deficient renal cell carcinoma